BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. Institutional ...

BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was down 19.5% compared to the same quarter last year. During the same period last year ...

BioNTech expects its revenues for the full ... with the closing of the Biotheus acquisition and with the resolved settlement of a contractual dispute with the National Institutes of Health ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key biopharma sector uncertainty but major economic worries ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

While BioNTech has evolved significantly since ... amount of approximately $800 million and payments derived from the settlement of the contractual disputes with NIH at the University of ...

BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into survival and become an immunotherapy powerhouse.

BioNTech expects its revenues for the full 2025 financial year to be in the range of €1,700 - €2,200 million and revenue phasing similar to 2024, primarily concentrated in the last three to ...

Biopharmaceutical company BioNTech SE(NASDAQ:BNTX) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1. ...